{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:11:04Z","timestamp":1787947864602,"version":"build-2784847793"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-09516-8","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:03:04Z","timestamp":1752656584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multi-scale machine learning model predicts muscle and functional disease progression"],"prefix":"10.1038","volume":"15","author":[{"given":"Silvia S.","family":"Blemker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Riem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"DuCharme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Pinette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn Eve","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Weatherley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Statland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Tapscott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W. W.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth D.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"9516_CR1","doi-asserted-by":"crossref","unstructured":"Denny, A. P. & Heather, A. K. Are Antioxidants a Potential Therapy for FSHD? A Review of the Literature. Oxid Med Cell Longev 7020295 (2017). (2017).","DOI":"10.1155\/2017\/7020295"},{"key":"9516_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00415-016-8361-3","volume":"264","author":"G Andersen","year":"2017","unstructured":"Andersen, G. et al. MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients. J. Neurol. 264, 438\u2013447 (2017).","journal-title":"J. Neurol."},{"key":"9516_CR3","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00415-019-09242-y","volume":"266","author":"JR Dahlqvist","year":"2019","unstructured":"Dahlqvist, J. R. et al. Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy. J. Neurol. 266, 1127\u20131135 (2019).","journal-title":"J. Neurol."},{"key":"9516_CR4","doi-asserted-by":"publisher","first-page":"e1211","DOI":"10.1212\/WNL.0000000000010155","volume":"95","author":"JR Dahlqvist","year":"2020","unstructured":"Dahlqvist, J. R. et al. Evaluation of inflammatory lesions over 2 years in facioscapulohumeral muscular dystrophy. Neurology 95, e1211\u2013e1221 (2020).","journal-title":"Neurology"},{"key":"9516_CR5","doi-asserted-by":"publisher","first-page":"e0183825","DOI":"10.1371\/journal.pone.0183825","volume":"12","author":"F Fatehi","year":"2017","unstructured":"Fatehi, F. et al. Long-term follow-up of MRI changes in thigh muscles of patients with facioscapulohumeral dystrophy: A quantitative study. PLoS One. 12, e0183825 (2017).","journal-title":"PLoS One"},{"key":"9516_CR6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/mus.26038","volume":"57","author":"MR Ferguson","year":"2018","unstructured":"Ferguson, M. R. et al. MRI change metrics of facioscapulohumeral muscular dystrophy: stir and T1. Muscle Nerve. 57, 905\u2013912 (2018).","journal-title":"Muscle Nerve"},{"key":"9516_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/mus.23911","volume":"49","author":"SD Friedman","year":"2014","unstructured":"Friedman, S. D. et al. Longitudinal features of STIR bright signal in FSHD. Muscle Nerve. 49, 257\u2013260 (2014).","journal-title":"Muscle Nerve"},{"key":"9516_CR8","doi-asserted-by":"publisher","first-page":"e85416","DOI":"10.1371\/journal.pone.0085416","volume":"9","author":"BH Janssen","year":"2014","unstructured":"Janssen, B. H. et al. Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration. PLoS One. 9, e85416 (2014).","journal-title":"PLoS One"},{"key":"9516_CR9","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/jcsm.12473","volume":"10","author":"M Monforte","year":"2019","unstructured":"Monforte, M. et al. Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging. J. Cachexia Sarcopenia Muscle. 10, 1258\u20131265 (2019).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"9516_CR10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12891-021-04134-7","volume":"22","author":"LH Wang","year":"2021","unstructured":"Wang, L. H. et al. Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy. BMC Musculoskelet. Disord. 22, 262 (2021).","journal-title":"BMC Musculoskelet. Disord"},{"key":"9516_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/mus.24287","volume":"51","author":"JJ Han","year":"2015","unstructured":"Han, J. J. et al. Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by kinect. Muscle Nerve. 51, 168\u2013175 (2015).","journal-title":"Muscle Nerve"},{"key":"9516_CR12","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00415-006-0230-z","volume":"253","author":"DB Olsen","year":"2006","unstructured":"Olsen, D. B., Gideon, P., Jeppesen, T. D. & Vissing, J. Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI. J. Neurol. 253, 1437\u20131441 (2006).","journal-title":"J. Neurol."},{"key":"9516_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.nmd.2009.02.009","volume":"19","author":"HE Kan","year":"2009","unstructured":"Kan, H. E. et al. Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul. Disord. 19, 357\u2013362 (2009).","journal-title":"Neuromuscul. Disord"},{"key":"9516_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/nbm.1494","volume":"23","author":"HE Kan","year":"2010","unstructured":"Kan, H. E. et al. Only fat infiltrated muscles in resting lower leg of FSHD patients show disturbed energy metabolism. NMR Biomed. 23, 563\u2013568 (2010).","journal-title":"NMR Biomed."},{"key":"9516_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mus.22342","volume":"45","author":"SD Friedman","year":"2012","unstructured":"Friedman, S. D. et al. The magnetic resonance imaging spectrum of facioscapulohumeral muscular dystrophy. Muscle Nerve. 45, 500\u2013506 (2012).","journal-title":"Muscle Nerve"},{"key":"9516_CR16","doi-asserted-by":"publisher","first-page":"e38779","DOI":"10.1371\/journal.pone.0038779","volume":"7","author":"G Tasca","year":"2012","unstructured":"Tasca, G. et al. Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles. PLoS One. 7, e38779 (2012).","journal-title":"PLoS One"},{"key":"9516_CR17","doi-asserted-by":"publisher","first-page":"e0132717","DOI":"10.1371\/journal.pone.0132717","volume":"10","author":"E Lareau-Trudel","year":"2015","unstructured":"Lareau-Trudel, E. et al. Muscle quantitative MR imaging and clustering analysis in patients with facioscapulohumeral muscular dystrophy type 1. PLoS One. 10, e0132717 (2015).","journal-title":"PLoS One"},{"key":"9516_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/mus.24569","volume":"52","author":"DG Leung","year":"2015","unstructured":"Leung, D. G., Carrino, J. A., Wagner, K. R. & Jacobs, M. A. Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy. Muscle Nerve. 52, 512\u2013520 (2015).","journal-title":"Muscle Nerve"},{"key":"9516_CR19","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1007\/s00415-018-9037-y","volume":"265","author":"K Mul","year":"2018","unstructured":"Mul, K. et al. Quantitative muscle MRI and ultrasound for facioscapulohumeral muscular dystrophy: complementary imaging biomarkers. J. Neurol. 265, 2646\u20132655 (2018).","journal-title":"J. Neurol."},{"key":"9516_CR20","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/hmg\/ddy364","volume":"28","author":"LH Wang","year":"2019","unstructured":"Wang, L. H. et al. MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD. Hum. Mol. Genet. 28, 476\u2013486 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"9516_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s43856-022-00217-1","volume":"2","author":"L Heskamp","year":"2022","unstructured":"Heskamp, L., Ogier, A., Bendahan, D. & Heerschap, A. Whole-muscle fat analysis identifies distal muscle end as disease initiation site in facioscapulohumeral muscular dystrophy. Commun. Med. (Lond). 2, 155 (2022).","journal-title":"Commun. Med. (Lond)"},{"key":"9516_CR22","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1212\/WNL.0000000000200757","volume":"99","author":"ML Mellion","year":"2022","unstructured":"Mellion, M. L. et al. Quantitative muscle analysis in FSHD using Whole-Body Fat-Referenced MRI: composite scores for longitudinal and Cross-sectional analysis. Neurology 99, e877\u2013e889 (2022).","journal-title":"Neurology"},{"key":"9516_CR23","doi-asserted-by":"crossref","unstructured":"Widholm, P. et al., Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole-body fat-referenced MRI: Protocol development, multicenter feasibility, and repeatability. Muscle Nerve (2022).","DOI":"10.1002\/mus.27638"},{"key":"9516_CR24","doi-asserted-by":"publisher","first-page":"15462","DOI":"10.1038\/s41598-024-65802-x","volume":"14","author":"L Riem","year":"2024","unstructured":"Riem, L. et al. AI driven analysis of MRI to measure health and disease progression in FSHD. Sci. Rep. 14, 15462 (2024).","journal-title":"Sci. Rep."},{"key":"9516_CR25","doi-asserted-by":"publisher","first-page":"e2103","DOI":"10.1212\/WNL.0000000000012882","volume":"97","author":"JN Dijkstra","year":"2021","unstructured":"Dijkstra, J. N. et al. Natural history of facioscapulohumeral dystrophy in children: A 2-Year Follow-up. Neurology 97, e2103\u2013e2113 (2021).","journal-title":"Neurology"},{"key":"9516_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.nmd.2022.11.006","volume":"33","author":"IR Woodcock","year":"2023","unstructured":"Woodcock, I. R., de Valle, K., Varma, N., Kean, M. & Ryan, M. M. Correlation between whole body muscle MRI and functional measures in paediatric patients with facioscapulohumeral muscular dystrophy. Neuromuscul. Disord. 33, 15\u201323 (2023).","journal-title":"Neuromuscul. Disord"},{"key":"9516_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ana.24599","volume":"79","author":"RJ Willcocks","year":"2016","unstructured":"Willcocks, R. J. et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large Duchenne muscular dystrophy cohort. Ann. Neurol. 79, 535\u2013547 (2016).","journal-title":"Ann. Neurol."},{"key":"9516_CR28","doi-asserted-by":"crossref","unstructured":"Sampson, J. H. et al., MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control. J Clin. Oncol 38 (2020).","DOI":"10.1200\/JCO.2020.38.15_suppl.2513"},{"key":"9516_CR29","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/acn3.51140","volume":"7","author":"N Zhou","year":"2020","unstructured":"Zhou, N. & Manser, P. Does including machine learning predictions in ALS clinical trial analysis improve statistical power? Ann. Clin. Transl Neurol. 7, 1756\u20131765 (2020).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"9516_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/17460441.2023.2273839","volume":"19","author":"M Bordukova","year":"2024","unstructured":"Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F. & Menden, M. P. Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. Expert Opin. Drug Discov. 19, 33\u201342 (2024).","journal-title":"Expert Opin. Drug Discov"},{"key":"9516_CR31","doi-asserted-by":"crossref","unstructured":"Wong, C. J. et al., Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progression. Hum Mol. Genet (2024).","DOI":"10.1093\/hmg\/ddae007"},{"key":"9516_CR32","first-page":"044009","volume":"6","author":"R Ni","year":"2019","unstructured":"Ni, R., Meyer, C. H., Blemker, S. S., Hart, J. M. & Feng, X. Automatic segmentation of all lower limb muscles from high-resolution magnetic resonance imaging using a cascaded three-dimensional deep convolutional neural network. J. Med. Imaging (Bellingham). 6, 044009 (2019).","journal-title":"J. Med. Imaging (Bellingham)"},{"key":"9516_CR33","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1007\/s10439-015-1488-z","volume":"44","author":"AC Santago","year":"2016","unstructured":"Santago, A. C. 2 Quantitative analysis of Three-Dimensional distribution and clustering of intramuscular fat in muscles of the rotator cuff. Ann. Biomed. Eng. 44, 2158\u20132167 (2016)., et al.","journal-title":"Ann. Biomed. Eng."},{"key":"9516_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12880-020-00423-0","volume":"20","author":"R Chang","year":"2020","unstructured":"Chang, R. et al. Percentage fat fraction in magnetic resonance imaging: upgrading the osteoporosis-detecting parameter. BMC Med. Imaging. 20, 30 (2020).","journal-title":"BMC Med. Imaging"},{"key":"9516_CR35","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3109\/21678421.2014.893361","volume":"15","author":"T Hothorn","year":"2014","unstructured":"Hothorn, T. & Jung, H. H. RandomForest4Life: a random forest for predicting ALS disease progression. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 444\u2013452 (2014).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener"},{"key":"9516_CR36","doi-asserted-by":"crossref","unstructured":"Ko, K. D., El-Ghazawi, T., Kim, D. & Morizono, H. & Pooled Resource Open-Access, A.L.S.C.T.C. Predicting the severity of motor neuron disease progression using electronic health record data with a cloud computing Big Data approach. IEEE Symp Comput Intell Bioinforma Comput Biol Proc 2014 (2014).","DOI":"10.1109\/CIBCB.2014.6845506"},{"key":"9516_CR37","unstructured":"Lundberg, S. M. & Lee, S. I. A unified approach to interpreting model predictions. Adv Neur in 30 (2017)."},{"key":"9516_CR38","doi-asserted-by":"publisher","first-page":"e70056","DOI":"10.1111\/cts.70056","volume":"17","author":"AV Ponce-Bobadilla","year":"2024","unstructured":"Ponce-Bobadilla, A. V., Schmitt, V., Maier, C. S., Mensing, S. & Stodtmann, S. Practical guide to SHAP analysis: explaining supervised machine learning model predictions in drug development. Clin. Transl Sci. 17, e70056 (2024).","journal-title":"Clin. Transl Sci."},{"key":"9516_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12891-020-03910-1","volume":"22","author":"LH Wang","year":"2021","unstructured":"Wang, L. H., Johnstone, L. M., Bindschadler, M., Tapscott, S. J. & Friedman, S. D. Adapting MRI as a clinical outcome measure for a facioscapulohumeral muscular dystrophy trial of prednisone and tacrolimus: case report. BMC Musculoskelet. Disord. 22, 56 (2021).","journal-title":"BMC Musculoskelet. Disord"},{"key":"9516_CR40","doi-asserted-by":"publisher","first-page":"1105276","DOI":"10.3389\/fneur.2023.1105276","volume":"14","author":"G Colelli","year":"2023","unstructured":"Colelli, G. et al. Radiomics and machine learning applied to STIR sequence for prediction of quantitative parameters in facioscapulohumeral disease. Front. Neurol. 14, 1105276 (2023).","journal-title":"Front. Neurol."},{"key":"9516_CR41","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.neurol.2016.08.002","volume":"172","author":"F Fatehi","year":"2016","unstructured":"Fatehi, F., Salort-Campana, E., Le Troter, A., Bendahan, D. & Attarian, S. Muscle MRI of facioscapulohumeral dystrophy (FSHD): A growing demand and a promising approach. Rev. Neurol. (Paris). 172, 566\u2013571 (2016).","journal-title":"Rev. Neurol. (Paris)"},{"key":"9516_CR42","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1212\/01.wnl.0000504577.93225.eb","volume":"87","author":"MR Ferguson","year":"2016","unstructured":"Ferguson, M. R. et al. Quantitative MRI reveals decelerated fatty infiltration in muscles of active FSHD patients. Neurology 87, 1746 (2016).","journal-title":"Neurology"},{"key":"9516_CR43","doi-asserted-by":"crossref","unstructured":"Fionda, L. et al., Comparison of quantitative muscle ultrasound and whole-body muscle MRI in facioscapulohumeral muscular dystrophy type 1 patients. Neurol Sci (2023).","DOI":"10.1007\/s10072-023-06842-5"},{"key":"9516_CR44","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1212\/WNL.0000000000004647","volume":"89","author":"K Mul","year":"2017","unstructured":"Mul, K. et al. Adding quantitative muscle MRI to the FSHD clinical trial toolbox. Neurology 89, 2057\u20132065 (2017).","journal-title":"Neurology"},{"key":"9516_CR45","doi-asserted-by":"publisher","first-page":"e100292","DOI":"10.1371\/journal.pone.0100292","volume":"9","author":"G Tasca","year":"2014","unstructured":"Tasca, G. et al. Upper girdle imaging in facioscapulohumeral muscular dystrophy. PLoS One. 9, e100292 (2014).","journal-title":"PLoS One"},{"key":"9516_CR46","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1002\/jcsm.13250","volume":"14","author":"SCC Vincenten","year":"2023","unstructured":"Vincenten, S. C. C. et al. Five-year follow-up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: the link to clinical outcome. J. Cachexia Sarcopenia Muscle. 14, 1695\u20131706 (2023).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"9516_CR47","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/hmg\/ddae007","volume":"33","author":"CJ Wong","year":"2024","unstructured":"Wong, C. J. et al. Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progression. Hum. Mol. Genet. 33, 698\u2013708 (2024).","journal-title":"Hum. Mol. Genet."},{"key":"9516_CR48","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/hmg\/ddaa031","volume":"29","author":"CJ Wong","year":"2020","unstructured":"Wong, C. J. et al. Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies. Hum. Mol. Genet. 29, 1030\u20131043 (2020).","journal-title":"Hum. Mol. Genet."},{"key":"9516_CR49","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10875-010-9474-6","volume":"31","author":"G Frisullo","year":"2011","unstructured":"Frisullo, G. et al. CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J. Clin. Immunol. 31, 155\u2013166 (2011).","journal-title":"J. Clin. Immunol."},{"key":"9516_CR50","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3233\/JND-230063","volume":"11","author":"A Greco","year":"2024","unstructured":"Greco, A. et al. IL-6 and TNF are potential inflammatory biomarkers in facioscapulohumeral muscular dystrophy. J. Neuromuscul. Dis. 11, 327\u2013347 (2024).","journal-title":"J. Neuromuscul. Dis."},{"key":"9516_CR51","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s12035-017-0563-x","volume":"55","author":"G Tasca","year":"2018","unstructured":"Tasca, G. et al. Muscle Microdialysis to investigate inflammatory biomarkers in facioscapulohumeral muscular dystrophy. Mol. Neurobiol. 55, 2959\u20132966 (2018).","journal-title":"Mol. Neurobiol."},{"key":"9516_CR52","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12968-021-00812-6","volume":"23","author":"E Blaszczyk","year":"2021","unstructured":"Blaszczyk, E. et al. Progressive myocardial injury in myotonic dystrophy type II and facioscapulohumeral muscular dystrophy 1: a cardiovascular magnetic resonance follow-up study. J. Cardiovasc. Magn. Reson. 23, 130 (2021).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"9516_CR53","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins, G. S., Reitsma, J. B., Altman, D. G. & Moons, K. G. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 350, g7594 (2015).","journal-title":"BMJ"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09516-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09516-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09516-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:27:56Z","timestamp":1757240876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09516-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9516"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09516-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.02.19.639046","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lara Riem, Olivia DuCharme, Megan Pinette, Kathryn Eve Costanzo, and Silvia Blemker are employees of Springbok Analytics. LR, EC, and OD have stock options to the company. SB is co-founder and owns stock in the company. FSHD Global is an investor in SB Analytics. JS is consultant or on advisory board for Avidity, Dyne, Fulcrum, Roche, Kate, Alnylam, Epicrispr, MiRecule, and Sanofi. SF is a consultant for Avidity, Dyne, Fulcrum, Kate, and Epicrispr. The remaining authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25339"}}